Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 15 Jun 2018 Results published in the Cancer Journal.
- 29 Jan 2018 Planned End Date changed from 1 Feb 2021 to 1 Feb 2019.
- 11 Oct 2016 Primary endpoint (Progression Free Survival (PFS)) has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History